ID   MYLK_HUMAN              Reviewed;        1914 AA.
AC   Q15746; O95796; O95797; O95798; O95799; Q14844; Q16794; Q5MY99;
AC   Q5MYA0; Q7Z4J0; Q9C0L5; Q9UBG5; Q9UIT9;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 4.
DT   02-NOV-2010, entry version 121.
DE   RecName: Full=Myosin light chain kinase, smooth muscle;
DE            Short=MLCK;
DE            EC=2.7.11.18;
DE   AltName: Full=Kinase-related protein;
DE            Short=KRP;
DE   AltName: Full=Telokin;
GN   Name=MYLK; Synonyms=MLCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND TISSUE SPECIFICITY.
RC   TISSUE=Hippocampus;
RX   MEDLINE=96121365; PubMed=8575746; DOI=10.1006/geno.1995.9965;
RA   Potier M.-C., Chelot E., Pekarsky Y., Gardiner K., Rossier J.,
RA   Turnell W.G.;
RT   "The human myosin light chain kinase (MLCK) from hippocampus: cloning,
RT   sequencing, expression, and localization to 3qcen-q21.";
RL   Genomics 29:562-570(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical vein endothelial cell;
RX   MEDLINE=97304466; PubMed=9160829;
RA   Garcia J.G.N., Lazar V.L., Gilbert-Mcclain L.I., Gallagher P.J.,
RA   Verin A.D.;
RT   "Myosin light chain kinase in endothelium: molecular cloning and
RT   regulation.";
RL   Am. J. Respir. Cell Mol. Biol. 16:489-494(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3A; 3B AND 4).
RC   TISSUE=Umbilical vein;
RX   MEDLINE=99216419; PubMed=10198165; DOI=10.1006/geno.1999.5774;
RA   Lazar V.L., Garcia J.G.N.;
RT   "A single human myosin light chain kinase gene (MLCK; MYLK).";
RL   Genomics 57:256-267(1999).
RN   [4]
RP   SEQUENCE REVISION (ISOFORMS 1 AND 2), PROTEIN SEQUENCE OF 457-476 AND
RP   968-985, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, PHOSPHORYLATION AT
RP   TYR-464 AND TYR-471, CALMODULIN-BINDING, AND ENZYME REGULATION.
RX   PubMed=11113114; DOI=10.1074/jbc.M005270200;
RA   Birukov K.G., Csortos C., Marzilli L., Dudek S., Ma S.-F.,
RA   Bresnick A.R., Verin A.D., Cotter R.J., Garcia J.G.N.;
RT   "Differential regulation of alternatively spliced endothelial cell
RT   myosin light chain kinase isoforms by p60(Src).";
RL   J. Biol. Chem. 276:8567-8573(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Intestinal epithelium;
RX   PubMed=15507455; DOI=10.1074/jbc.M408822200;
RA   Clayburgh D.R., Rosen S., Witkowski E.D., Wang F., Blair S., Dudek S.,
RA   Garcia J.G., Alverdy J.C., Turner J.R.;
RT   "A differentiation-dependent splice variant of myosin light chain
RT   kinase, MLCK1, regulates epithelial tight junction permeability.";
RL   J. Biol. Chem. 279:55506-55513(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15020676; DOI=10.1242/jcs.00993;
RA   Dulyaninova N.G., Patskovsky Y.V., Bresnick A.R.;
RT   "The N-terminus of the long MLCK induces a disruption in normal
RT   spindle morphology and metaphase arrest.";
RL   J. Cell Sci. 117:1481-1493(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Cervix carcinoma;
RA   Kikuchi A., Murata-Hori M., Hosoya H.;
RT   "HeLa myosin light chain kinase.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1456-1914.
RC   TISSUE=Placenta;
RA   Watterson D.M.;
RL   Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1614-1914 (ISOFORMS 5 AND
RP   6), AND TISSUE SPECIFICITY.
RC   TISSUE=Lung, and Placenta;
RX   MEDLINE=20007838; PubMed=10536370;
RX   DOI=10.1002/(SICI)1097-4644(19991201)75:3<481::AID-JCB12>3.3.CO;2-X;
RA   Watterson D.M., Schavocky J.P., Guo L., Weiss C., Chlenski A.,
RA   Shrinsky V.P., Van Eldik L.J., Haiech J.;
RT   "Analysis of the kinase-related protein gene found at human chromosome
RT   3q21 in a multi-gene cluster: organization, expression, alternative
RT   splicing and polymorphic marker.";
RL   J. Cell. Biochem. 75:481-491(1999).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1438; SER-1760;
RP   SER-1772; THR-1774; SER-1776; THR-1778 AND SER-1779, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1438, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1779, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   STRUCTURE BY NMR OF 1238-1338.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the eighth Ig-like domain of human myosin light
RT   chain kinase.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-261; ALA-276; HIS-378; VAL-405;
RP   SER-443; GLY-607; ALA-652; CYS-656; MET-692; THR-701; MET-709;
RP   VAL-1527 AND LEU-1588.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium/calmodulin-dependent enzyme implicated in smooth
CC       muscle contraction via phosphorylation of myosin light chains
CC       (MLC). Also regulates actin-myosin interaction through a non-
CC       kinase activty (By similarity). Implicated in the regulation of
CC       endothelial as well as vascular permeability. In the nervous
CC       system it has been shown to control the growth initiation of
CC       astrocytic processes in culture and to participate in transmitter
CC       release at synapses formed between cultured sympathetic ganglion
CC       cells. Critical participant in signaling sequences that result in
CC       fibroblast apoptosis.
CC   -!- CATALYTIC ACTIVITY: ATP + [myosin light-chain] = ADP + [myosin
CC       light-chain] phosphate.
CC   -!- COFACTOR: Magnesium.
CC   -!- COFACTOR: Calcium.
CC   -!- ENZYME REGULATION: Isoform 1 is activated by phosphorylation on
CC       Tyr-464 and Tyr-471. Isoforms which lack these tyrosine residues
CC       are not regulated in this way. All catalytically active isoforms
CC       require binding to calcium and calmodulin for activation.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.5 uM for MLC (isoform 1 at 22 degrees Celsius);
CC         KM=7.2 uM for MLC (isoform 2 at 22 degrees Celsius);
CC         Vmax=11.9 umol/min/mg enzyme (isoform 1 at 22 degrees Celsius);
CC         Vmax=10.9 umol/min/mg enzyme (isoform 1 at 22 degrees Celsius);
CC   -!- SUBUNIT: All isoforms including Telokin bind calmodulin. Interacts
CC       with SVIL (By similarity).
CC   -!- INTERACTION:
CC       P62993:GRB2; NbExp=1; IntAct=EBI-968482, EBI-401755;
CC       P16333:NCK1; NbExp=1; IntAct=EBI-968482, EBI-389883;
CC       P27986:PIK3R1; NbExp=1; IntAct=EBI-968482, EBI-79464;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=8;
CC         Comment=Additional isoforms seem to exist;
CC       Name=1; Synonyms=Non-muscle isozyme;
CC         IsoId=Q15746-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15746-2; Sequence=VSP_004791;
CC       Name=3A;
CC         IsoId=Q15746-3; Sequence=VSP_004794;
CC         Note=Ref.3 (AAD15922) sequence differs from that shown due to
CC         frameshifts in positions 1433 and 1439;
CC       Name=3B;
CC         IsoId=Q15746-4; Sequence=VSP_004791, VSP_004794;
CC         Note=Ref.3 (AAD15923) sequence differs from that shown due to
CC         frameshifts in positions 1433 and 1439;
CC       Name=4;
CC         IsoId=Q15746-5; Sequence=VSP_004793;
CC         Note=Ref.3 (AAD15924) sequence differs from that shown due to
CC         frameshifts in positions 1433 and 1439;
CC       Name=Del-1790;
CC         IsoId=Q15746-6; Sequence=VSP_004795;
CC       Name=5; Synonyms=Smooth-muscle isozyme;
CC         IsoId=Q15746-7; Sequence=VSP_018845;
CC         Note=Produced by alternative initiation at Met-923 of isoform 1;
CC       Name=6; Synonyms=Telokin;
CC         IsoId=Q15746-8; Sequence=VSP_018846;
CC         Note=Produced by alternative initiation at Met-1761 of isoform
CC         1. Has no catalytic activity;
CC   -!- TISSUE SPECIFICITY: Smooth muscle and non-muscle isozymes are
CC       expressed in a wide variety of adult and fetal tissues and in
CC       cultured endothelium with qualitative expression appearing to be
CC       neither tissue- nor development-specific. Non-muscle isoform 2 is
CC       the dominant splice variant expressed in various tissues. Telokin
CC       has been found in a wide variety of adult and fetal tissues.
CC   -!- PTM: MLCK is probably down-regulated by phosphorylation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family.
CC   -!- SIMILARITY: Contains 1 fibronectin type-III domain.
CC   -!- SIMILARITY: Contains 9 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Myosin light-chain kinase
CC       entry;
CC       URL="http://en.wikipedia.org/wiki/Myosin_light-chain_kinase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X85337; CAA59685.1; -; mRNA.
DR   EMBL; U48959; AAC18423.2; -; mRNA.
DR   EMBL; AF069601; AAD15921.2; -; mRNA.
DR   EMBL; AF069602; AAD15922.1; ALT_FRAME; mRNA.
DR   EMBL; AF069603; AAD15923.1; ALT_FRAME; mRNA.
DR   EMBL; AF069604; AAD15924.1; ALT_FRAME; mRNA.
DR   EMBL; AY424269; AAR29061.1; -; mRNA.
DR   EMBL; AY424270; AAR29062.1; -; mRNA.
DR   EMBL; AY339601; AAQ02673.1; -; mRNA.
DR   EMBL; AB037663; BAB21504.1; -; mRNA.
DR   EMBL; X90870; CAA62378.1; -; mRNA.
DR   EMBL; AC020634; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC023165; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF096771; AAD51380.1; -; Genomic_DNA.
DR   EMBL; AF096766; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096767; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096768; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096769; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096770; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096771; AAD51381.1; -; Genomic_DNA.
DR   EMBL; AF096769; AAD51381.1; JOINED; Genomic_DNA.
DR   EMBL; AF096770; AAD51381.1; JOINED; Genomic_DNA.
DR   EMBL; AF096774; AAD54018.1; -; mRNA.
DR   IPI; IPI00221255; -.
DR   IPI; IPI00221259; -.
DR   IPI; IPI00336081; -.
DR   IPI; IPI00736561; -.
DR   IPI; IPI00791032; -.
DR   IPI; IPI00791924; -.
DR   IPI; IPI00855853; -.
DR   IPI; IPI00955810; -.
DR   RefSeq; NP_444253.3; -.
DR   RefSeq; NP_444254.3; -.
DR   RefSeq; NP_444255.3; -.
DR   RefSeq; NP_444256.3; -.
DR   RefSeq; NP_444259.1; -.
DR   UniGene; Hs.477375; -.
DR   UniGene; Hs.625965; -.
DR   PDB; 2CQV; NMR; -; A=1238-1338.
DR   PDB; 2K0F; NMR; -; B=1742-1760.
DR   PDB; 2YR3; NMR; -; A=510-601.
DR   PDBsum; 2CQV; -.
DR   PDBsum; 2K0F; -.
DR   PDBsum; 2YR3; -.
DR   ProteinModelPortal; Q15746; -.
DR   IntAct; Q15746; 11.
DR   MINT; MINT-2807402; -.
DR   STRING; Q15746; -.
DR   PhosphoSite; Q15746; -.
DR   PRIDE; Q15746; -.
DR   Ensembl; ENST00000360304; ENSP00000353452; ENSG00000065534.
DR   Ensembl; ENST00000361290; ENSP00000355024; ENSG00000065534.
DR   Ensembl; ENST00000475616; ENSP00000418335; ENSG00000065534.
DR   GeneID; 4638; -.
DR   KEGG; hsa:4638; -.
DR   UCSC; uc003egn.1; human.
DR   UCSC; uc003egq.1; human.
DR   UCSC; uc003egr.1; human.
DR   CTD; 4638; -.
DR   GeneCards; GC03M123281; -.
DR   HGNC; HGNC:7590; MYLK.
DR   HPA; CAB009628; -.
DR   HPA; CAB020789; -.
DR   MIM; 600922; gene.
DR   PharmGKB; PA31388; -.
DR   eggNOG; prNOG08014; -.
DR   HOVERGEN; HBG052551; -.
DR   InParanoid; Q15746; -.
DR   PhylomeDB; Q15746; -.
DR   BRENDA; 2.7.11.18; 247.
DR   Pathway_Interaction_DB; aurora_b_pathway; Aurora B signaling.
DR   Reactome; REACT_17044; Muscle contraction.
DR   NextBio; 17860; -.
DR   ArrayExpress; Q15746; -.
DR   Bgee; Q15746; -.
DR   Genevestigator; Q15746; -.
DR   GermOnline; ENSG00000065534; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004687; F:myosin light chain kinase activity; TAS:ProtInc.
DR   GO; GO:0006936; P:muscle contraction; EXP:Reactome.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR015725; Myosin_light_chain_kin.
DR   InterPro; IPR020675; Myosin_light_chain_kin-rel.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 10.
DR   PANTHER; PTHR22964; Myosin_light_chain_kin-rel; 1.
DR   PANTHER; PTHR22964:SF3; Myosin_lt_kin; 1.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF07679; I-set; 9.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00060; FN3; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 8.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49265; FN_III-like; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS50835; IG_LIKE; 9.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Alternative initiation;
KW   Alternative splicing; ATP-binding; Calcium; Calmodulin-binding;
KW   Complete proteome; Direct protein sequencing; Immunoglobulin domain;
KW   Kinase; Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Repeat; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1   1914       Myosin light chain kinase, smooth muscle.
FT                                /FTId=PRO_0000024354.
FT   DOMAIN       33    122       Ig-like C2-type 1.
FT   DOMAIN      161    249       Ig-like C2-type 2.
FT   DOMAIN      414    503       Ig-like C2-type 3.
FT   DOMAIN      514    599       Ig-like C2-type 4.
FT   DOMAIN      620    711       Ig-like C2-type 5.
FT   DOMAIN      721    821       Ig-like C2-type 6.
FT   REPEAT      868    895       1-1.
FT   REPEAT      896    923       1-2.
FT   REPEAT      924    951       1-3.
FT   REPEAT      952    979       1-4.
FT   REPEAT      980    998       1-5; truncated.
FT   REPEAT      999   1003       2-1; truncated.
FT   REPEAT     1004   1015       2-2.
FT   REPEAT     1016   1027       2-3.
FT   REPEAT     1028   1039       2-4.
FT   REPEAT     1040   1051       2-5.
FT   REPEAT     1052   1063       2-6.
FT   DOMAIN     1098   1186       Ig-like C2-type 7.
FT   DOMAIN     1238   1326       Ig-like C2-type 8.
FT   DOMAIN     1331   1422       Fibronectin type-III.
FT   DOMAIN     1464   1719       Protein kinase.
FT   DOMAIN     1809   1898       Ig-like C2-type 9.
FT   NP_BIND    1470   1478       ATP (By similarity).
FT   REGION      868    998       5 X 28 AA approximate tandem repeats.
FT   REGION      923    963       Actin-binding (calcium/calmodulin-
FT                                sensitive) (By similarity).
FT   REGION      948    963       Calmodulin-binding (By similarity).
FT   REGION      999   1063       6 X 12 AA approximate tandem repeats.
FT   REGION     1061   1460       Actin-binding (calcium/calmodulin-
FT                                insensitive) (By similarity).
FT   REGION     1711   1774       Calmodulin-binding.
FT   COMPBIAS   1906   1914       Poly-Glu.
FT   ACT_SITE   1585   1585       Proton acceptor (By similarity).
FT   BINDING    1493   1493       ATP (By similarity).
FT   MOD_RES     343    343       Phosphoserine (By similarity).
FT   MOD_RES     464    464       Phosphotyrosine.
FT   MOD_RES     471    471       Phosphotyrosine.
FT   MOD_RES     814    814       Phosphoserine (By similarity).
FT   MOD_RES    1438   1438       Phosphoserine.
FT   MOD_RES    1759   1759       Phosphoserine (By similarity).
FT   MOD_RES    1760   1760       Phosphoserine.
FT   MOD_RES    1772   1772       Phosphoserine.
FT   MOD_RES    1774   1774       Phosphothreonine.
FT   MOD_RES    1776   1776       Phosphoserine.
FT   MOD_RES    1778   1778       Phosphothreonine.
FT   MOD_RES    1779   1779       Phosphoserine.
FT   VAR_SEQ       1   1760       Missing (in isoform 6).
FT                                /FTId=VSP_018846.
FT   VAR_SEQ       1    922       Missing (in isoform 5).
FT                                /FTId=VSP_018845.
FT   VAR_SEQ     437    506       VSGIPKPEVAWFLEGTPVRRQEGSIEVYEDAGSHYLCLLKA
FT                                RTRDSGTYSCTASNAQGQLSCSWTLQVER -> G (in
FT                                isoform 2 and isoform 3B).
FT                                /FTId=VSP_004791.
FT   VAR_SEQ    1473   1545       Missing (in isoform 4).
FT                                /FTId=VSP_004793.
FT   VAR_SEQ    1655   1705       Missing (in isoform 3A and isoform 3B).
FT                                /FTId=VSP_004794.
FT   VAR_SEQ    1790   1790       Missing (in isoform Del-1790).
FT                                /FTId=VSP_004795.
FT   VARIANT      21     21       P -> H (in dbSNP:rs28497577).
FT                                /FTId=VAR_057106.
FT   VARIANT     261    261       V -> A (in dbSNP:rs3796164).
FT                                /FTId=VAR_040847.
FT   VARIANT     276    276       T -> A.
FT                                /FTId=VAR_040848.
FT   VARIANT     336    336       P -> L (in dbSNP:rs35912339).
FT                                /FTId=VAR_057107.
FT   VARIANT     378    378       R -> H.
FT                                /FTId=VAR_040849.
FT   VARIANT     405    405       M -> V (in dbSNP:rs35436690).
FT                                /FTId=VAR_040850.
FT   VARIANT     443    443       P -> S.
FT                                /FTId=VAR_040851.
FT   VARIANT     607    607       R -> G.
FT                                /FTId=VAR_040852.
FT   VARIANT     652    652       P -> A.
FT                                /FTId=VAR_040853.
FT   VARIANT     656    656       W -> C.
FT                                /FTId=VAR_040854.
FT   VARIANT     692    692       T -> M.
FT                                /FTId=VAR_040855.
FT   VARIANT     701    701       A -> T.
FT                                /FTId=VAR_040856.
FT   VARIANT     709    709       V -> M.
FT                                /FTId=VAR_040857.
FT   VARIANT     845    845       R -> C (in dbSNP:rs3732485).
FT                                /FTId=VAR_057108.
FT   VARIANT     861    861       L -> P (in dbSNP:rs3732486).
FT                                /FTId=VAR_019986.
FT   VARIANT     877    877       V -> M (in dbSNP:rs34542174).
FT                                /FTId=VAR_057109.
FT   VARIANT     914    914       D -> E (in dbSNP:rs3732487).
FT                                /FTId=VAR_019987.
FT   VARIANT    1527   1527       A -> V.
FT                                /FTId=VAR_040858.
FT   VARIANT    1588   1588       P -> L (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040859.
FT   CONFLICT    147    147       P -> S (in Ref. 2; AAC18423, 3; AAD15922/
FT                                AAD15923, 5; AAR29062 and 6; AAQ02673).
FT   CONFLICT    466    466       D -> N (in Ref. 5; AAR29062).
FT   CONFLICT    496    496       L -> V (in Ref. 2; AAC18423, 3; AAD15922,
FT                                5; AAR29062 and 6; AAQ02673).
FT   CONFLICT    681    681       C -> W (in Ref. 2; AAC18423 and 3;
FT                                AAD15921/AAD15922/AAD15923).
FT   CONFLICT    933    933       V -> M (in Ref. 1; CAA59685).
FT   CONFLICT    963    963       S -> P (in Ref. 3; AAD15922).
FT   CONFLICT   1022   1022       P -> A (in Ref. 1; CAA59685).
FT   CONFLICT   1048   1050       KPM -> EAH (in Ref. 1 and 7).
FT   CONFLICT   1162   1162       P -> L (in Ref. 3; AAD15922/AAD15923).
FT   CONFLICT   1210   1210       L -> P (in Ref. 1; CAA59685).
FT   CONFLICT   1280   1280       E -> D (in Ref. 3; AAD15922/AAD15923).
FT   CONFLICT   1284   1284       M -> I (in Ref. 3; AAD15922/AAD15923/
FT                                AAD15924).
FT   CONFLICT   1300   1300       A -> G (in Ref. 1; CAA59685).
FT   CONFLICT   1316   1316       L -> S (in Ref. 1; CAA59685).
FT   CONFLICT   1326   1326       T -> S (in Ref. 1; CAA59685).
FT   CONFLICT   1478   1478       V -> C (in Ref. 1; CAA59685).
FT   CONFLICT   1511   1511       S -> T (in Ref. 3; AAD15922/AAD15923).
FT   CONFLICT   1518   1518       H -> P (in Ref. 5; AAR29061/AAR29062).
FT   CONFLICT   1563   1563       I -> T (in Ref. 1; CAA59685).
FT   CONFLICT   1609   1609       A -> P (in Ref. 1; CAA59685).
FT   CONFLICT   1634   1634       N -> I (in Ref. 5; AAR29061/AAR29062).
FT   CONFLICT   1639   1640       GY -> D (in Ref. 3; AAD15922/AAD15923/
FT                                AAD15924).
FT   CONFLICT   1639   1639       G -> R (in Ref. 1; CAA59685).
FT   CONFLICT   1648   1648       G -> R (in Ref. 1; CAA59685).
FT   CONFLICT   1658   1659       LS -> PF (in Ref. 1; CAA59685).
FT   CONFLICT   1676   1676       A -> P (in Ref. 5; AAR29061/AAR29062).
FT   CONFLICT   1710   1711       CT -> LA (in Ref. 1; CAA59685).
FT   CONFLICT   1897   1897       L -> H (in Ref. 3; AAD15922/AAD15923/
FT                                AAD15924).
FT   STRAND      512    518
FT   STRAND      523    526
FT   STRAND      531    534
FT   STRAND      536    541
FT   STRAND      546    553
FT   STRAND      560    562
FT   STRAND      565    570
FT   STRAND      581    586
FT   STRAND      591    595
SQ   SEQUENCE   1914 AA;  210715 MW;  2D094E161CE2D4BA CRC64;
     MGDVKLVASS HISKTSLSVD PSRVDSMPLT EAPAFILPPR NLCIKEGATA KFEGRVRGYP
     EPQVTWHRNG QPITSGGRFL LDCGIRGTFS LVIHAVHEED RGKYTCEATN GSGARQVTVE
     LTVEGSFAKQ LGQPVVSKTL GDRFSAPAVE TRPSIWGECP PKFATKLGRV VVKEGQMGRF
     SCKITGRPQP QVTWLKGNVP LQPSARVSVS EKNGMQVLEI HGVNQDDVGV YTCLVVNGSG
     KASMSAELSI QGLDSANRSF VRETKATNSD VRKEVTNVIS KESKLDSLEA AAKSKNCSSP
     QRGGSPPWAA NSQPQPPRES KLESCKDSPR TAPQTPVLQK TSSSITLQAA RVQPEPRAPG
     LGVLSPSGEE RKRPAPPRPA TFPTRQPGLG SQDVVSKAAN RRIPMEGQRD SAFPKFESKP
     QSQEVKENQT VKFRCEVSGI PKPEVAWFLE GTPVRRQEGS IEVYEDAGSH YLCLLKARTR
     DSGTYSCTAS NAQGQLSCSW TLQVERLAVM EVAPSFSSVL KDCAVIEGQD FVLQCSVRGT
     PVPRITWLLN GQPIQYARST CEAGVAELHI QDALPEDHGT YTCLAENALG QVSCSAWVTV
     HEKKSSRKSE YLLPVAPSKP TAPIFLQGLS DLKVMDGSQV TMTVQVSGNP PPEVIWLHNG
     NEIQESEDFH FEQRGTQHSL CIQEVFPEDT GTYTCEAWNS AGEVRTQAVL TVQEPHDGTQ
     PWFISKPRSV TASLGQSVLI SCAIAGDPFP TVHWLRDGKA LCKDTGHFEV LQNEDVFTLV
     LKKVQPWHAG QYEILLKNRV GECSCQVSLM LQNSSARALP RGREPASCED LCGGGVGADG
     GGSDRYGSLR PGWPARGQGW LEEEDGEDVR GVLKRRVETR QHTEEAIRQQ EVEQLDFRDL
     LGKKVSTKTL SEDDLKEIPA EQMDFRANLQ RQVKPKTVSE EERKVHSPQQ VDFRSVLAKK
     GTSKTPVPEK VPPPKPATPD FRSVLGGKKK LPAENGSSSA ETLNAKAVES SKPLSNAQPS
     GPLKPVGNAK PAETLKPMGN AKPAETLKPM GNAKPDENLK SASKEELKKD VKNDVNCKRG
     HAGTTDNEKR SESQGTAPAF KQKLQDVHVA EGKKLLLQCQ VSSDPPATII WTLNGKTLKT
     TKFIILSQEG SLCSVSIEKA LPEDRGLYKC VAKNDAGQAE CSCQVTVDDA PASENTKAPE
     MKSRRPKSSL PPVLGTESDA TVKKKPAPKT PPKAAMPPQI IQFPEDQKVR AGESVELFGK
     VTGTQPITCT WMKFRKQIQE SEHMKVENSE NGSKLTILAA RQEHCGCYTL LVENKLGSRQ
     AQVNLTVVDK PDPPAGTPCA SDIRSSSLTL SWYGSSYDGG SAVQSYSIEI WDSANKTWKE
     LATCRSTSFN VQDLLPDHEY KFRVRAINVY GTSEPSQESE LTTVGEKPEE PKDEVEVSDD
     DEKEPEVDYR TVTINTEQKV SDFYDIEERL GSGKFGQVFR LVEKKTRKVW AGKFFKAYSA
     KEKENIRQEI SIMNCLHHPK LVQCVDAFEE KANIVMVLEI VSGGELFERI IDEDFELTER
     ECIKYMRQIS EGVEYIHKQG IVHLDLKPEN IMCVNKTGTR IKLIDFGLAR RLENAGSLKV
     LFGTPEFVAP EVINYEPIGY ATDMWSIGVI CYILVSGLSP FMGDNDNETL ANVTSATWDF
     DDEAFDEISD DAKDFISNLL KKDMKNRLDC TQCLQHPWLM KDTKNMEAKK LSKDRMKKYM
     ARRKWQKTGN AVRAIGRLSS MAMISGLSGR KSSTGSPTSP LNAEKLESEE DVSQAFLEAV
     AEEKPHVKPY FSKTIRDLEV VEGSAARFDC KIEGYPDPEV VWFKDDQSIR ESRHFQIDYD
     EDGNCSLIIS DVCGDDDAKY TCKAVNSLGE ATCTAELIVE TMEEGEGEGE EEEE
//
